Skip to content
OpenCapital
Get started

Intellia Therapeutics NTLA Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

ALN
Alnylam PharmaceuticalsALNY
$45.66M-0.8%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$18.61M+6.3%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$14.78M+11.9%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$1.8M+32.2%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$3.89M-34.4%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$13M+8.3%

Other financials

Income statement

See full
Revenue$15.0M-9.5%
Operating income-$100.5M+16.8%
Net income-$96.2M+15.8%
EPS (diluted)-$0.81+26.4%

Balance sheet

See full
Cash & equivalents$134.7M+6.2%
Total debt$80.5M-32.5%
Total equity$620.9M-20.4%
Total assets$758.8M-23.1%

Cash flow

See full
Operating cash flow-$117.3M+21.2%
CapEx$79.0K-89.3%
Free cash flow-$117.4M+21.5%

Valuation

See full
Market cap$2.13B+106%
Enterprise value$2.08B+100%
P/S32.2×+9.5×

Profitability

See full
Operating margin-636.6%-202pp
Net margin-597%-194pp
FCF margin-550.2%-140pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×0.0×
Current ratio6.1×+1.2×

Where this comes from

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Intellia Therapeutics's operating lease liabilities (current)?
Intellia Therapeutics (NTLA) reported operating lease liabilities (current) of $19.1M in Q1 2026.
How has Intellia Therapeutics's operating lease liabilities (current) changed year-over-year?
Intellia Therapeutics's operating lease liabilities (current) decreased by 50.7% year-over-year, from $38.76M to $19.1M.
What is the long-term trend for Intellia Therapeutics's operating lease liabilities (current)?
Over 5 years (2020 to 2025), Intellia Therapeutics's operating lease liabilities (current) has grown at a 36.0% compound annual growth rate (CAGR), from $5.7M to $26.48M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.